Thus, the knockout of ATG7, Beclin-1, or treatment with CQ restored the antitumor effect of docetaxel, demonstrating that either autophagy or FOXM1 may be potential targets for combined therapies with docetaxel to treat metastatic prostate cancer patients (81). Here, FOXM1 is linked to prostate carcinoma.